Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review

CONCLUSIONS: Antiresorptive therapy with either a bisphosphonate (i.e., alendronate) or raloxifene could be considered a sequential antiosteoporosis therapy after MHT withdrawal since they have been shown in studies to further increase BMD. However, no safe conclusions can be drawn from the existing literature.PMID:38236381 | DOI:10.1007/s42000-024-00526-1

Source: Hormones - January 18, 2024 Category: Endocrinology Authors: Panagiotis Anagnostis Efstathios Divaris Julia Κ Bosdou Symeon Tournis Konstantinos Stathopoulos Dimitrios G Goulis Source Type: research